Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
111 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2015', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Renal Failure (ARF) (Acute Kidney Injury) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 9 Therapeutics Development 10 Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview 10 Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis 11 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Development by Companies 12 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics under Investigation by Universities/Institutes 15 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Products Glance 16 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Development by Companies 19 Acute Renal Failure (ARF) (Acute Kidney Injury) - Products under Investigation by Universities/Institutes 21 Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development 22 ACROVIS biostructures GmbH 22 Adrenomed AG 23 Am-Pharma B.V. 24 Angion Biomedica Corp. 25 Bolder Biotechnology, Inc. 26 Cellmid Limited 27 DiaMedica Inc. 28 Digna Biotech, S.L. 29 F. Hoffmann-La Roche Ltd. 30 G1 Therapeutics, Inc. 31 Hadasit Medical Research Services & Development Ltd 32 Kringle Pharma, Inc. 33 NephroGenex, Inc. 34 Noorik Biopharmaceuticals AG 35 Nyken BV 36 Opsona Therapeutics Ltd. 37 Quark Pharmaceuticals, Inc. 38 STATegics, Inc. 39 Thrasos, Inc. 40 Torrent Pharmaceuticals Limited 41 Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Target 43 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 adrecizumab - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 BB-3 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 BBT-030 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 BBT-045 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 CAB-101 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 cardiotrophin-1 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cell Therapy to Activate Wnt7b for Kidney Injury - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CXA-10 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 DM-199 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 HYPER-IL-6 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 KP-100IT - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 MTP-131 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 N-003 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 NOXD-21 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NYK-1341 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 OPN-305 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Pyridoxamine Dihydrochloride - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 QPI-1002 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 R-190 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Recombinant Human Alkaline Phosphatase - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 RO-6839328 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecule to Activate Heat Shock Protein 70 (Hsp70) for Delayed Graft Function - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecules for Acute Renal Failure - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 STSE-15 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 THR-184 - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 TRC-160334 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Acute Renal Failure (ARF) (Acute Kidney Injury) - Recent Pipeline Updates 90 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects 102 Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products 103 Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones 104 Featured News & Press Releases 104 Dec 15, 2014: Complexa Initiates Phase 1B Study of CXA-10 in Acute Kidney Injury 104 Nov 13, 2014: AM-Pharma Presents Preclinical Data On Mode-Of-Action For RecAP In Acute Kidney Injury 104 Sep 16, 2014: Thrasos Announces Successful Formal Interim Analysis and Clinical Update for Phase 2 Study of THR-184 for Acute Kidney Injury 105 Jul 01, 2014: Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients 106 May 01, 2014: Complexa Initiates First Clinical Trial of CXA-10 for Acute Kidney Injury 106 Mar 26, 2014: AM-Pharma announces positive Phase I data on recAP for Acute Kidney Injury 107 Feb 04, 2014: FDA Grants Thrasos Fast Track Designation for THR-184 in Acute Kidney Injury 107 Jan 28, 2014: American Journal of Kidney Disease publishes review article of Alkaline Phosphatase 108 Nov 08, 2013: AM-Pharma Presents Positive Data from recAP Preclinical Study at ASN Meeting 108 Sep 23, 2013: AM-Pharma Returns to Clinic with Phase I Trial of New Recombinant Human Alkaline Phosphatase to Treat Acute Kidney Injury 109 Appendix 110 Methodology 110 Coverage 110 Secondary Research 110 Primary Research 110 Expert Panel Validation 110 Contact Us 111 Disclaimer 111
List of Tables Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2015 10 Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2015 15 Comparative Analysis by Clinical Stage Development, H1 2015 16 Comparative Analysis by Early Stage Development, H1 2015 17 Comparative Analysis by Unknown Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by ACROVIS biostructures GmbH, H1 2015 22 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Adrenomed AG, H1 2015 23 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Am-Pharma B.V., H1 2015 24 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Angion Biomedica Corp., H1 2015 25 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Bolder Biotechnology, Inc., H1 2015 26 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Cellmid Limited, H1 2015 27 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by DiaMedica Inc., H1 2015 28 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Digna Biotech, S.L., H1 2015 29 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 30 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by G1 Therapeutics, Inc., H1 2015 31 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 32 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Kringle Pharma, Inc., H1 2015 33 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by NephroGenex, Inc., H1 2015 34 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Noorik Biopharmaceuticals AG, H1 2015 35 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Nyken BV, H1 2015 36 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Opsona Therapeutics Ltd., H1 2015 37 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Quark Pharmaceuticals, Inc., H1 2015 38 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by STATegics, Inc., H1 2015 39 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Thrasos, Inc., H1 2015 40 Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Torrent Pharmaceuticals Limited, H1 2015 41 Assessment by Monotherapy Products, H1 2015 42 Number of Products by Stage and Target, H1 2015 44 Number of Products by Stage and Mechanism of Action, H1 2015 46 Number of Products by Stage and Route of Administration, H1 2015 48 Number of Products by Stage and Molecule Type, H1 2015 50 Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Recent Pipeline Updates, H1 2015 90 Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2015 102 Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2015 103
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.